Wealth Enhancement Advisory Services LLC Boosts Holdings in GSK plc (NYSE:GSK)

Wealth Enhancement Advisory Services LLC lifted its position in GSK plc (NYSE:GSKFree Report) by 2.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 157,266 shares of the pharmaceutical company’s stock after acquiring an additional 4,082 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in GSK were worth $6,742,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. Fisher Asset Management LLC boosted its position in shares of GSK by 10.8% during the fourth quarter. Fisher Asset Management LLC now owns 15,065,558 shares of the pharmaceutical company’s stock valued at $558,330,000 after buying an additional 1,465,165 shares during the period. Primecap Management Co. CA increased its stake in GSK by 0.3% in the fourth quarter. Primecap Management Co. CA now owns 12,089,370 shares of the pharmaceutical company’s stock worth $448,032,000 after purchasing an additional 30,600 shares during the period. Royal Bank of Canada boosted its stake in shares of GSK by 5.1% during the third quarter. Royal Bank of Canada now owns 8,079,897 shares of the pharmaceutical company’s stock valued at $292,896,000 after purchasing an additional 389,871 shares during the period. Morgan Stanley boosted its stake in shares of GSK by 2.1% during the third quarter. Morgan Stanley now owns 7,551,555 shares of the pharmaceutical company’s stock valued at $273,744,000 after purchasing an additional 156,480 shares during the period. Finally, Provident Trust Co. increased its stake in GSK by 53.6% in the 4th quarter. Provident Trust Co. now owns 3,716,830 shares of the pharmaceutical company’s stock worth $137,746,000 after buying an additional 1,297,385 shares during the period. 15.74% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have issued reports on GSK. Citigroup raised shares of GSK to a “strong-buy” rating in a research report on Monday, June 24th. Berenberg Bank upgraded GSK to a “strong-buy” rating in a report on Thursday, June 20th. Guggenheim upgraded GSK from a “neutral” rating to a “buy” rating in a report on Monday, March 4th. Finally, The Goldman Sachs Group assumed coverage on GSK in a research note on Thursday, May 30th. They set a “neutral” rating and a $47.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, two have assigned a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat, GSK has an average rating of “Moderate Buy” and a consensus price target of $47.00.

Read Our Latest Research Report on GSK

GSK Stock Down 0.4 %

Shares of NYSE GSK opened at $38.50 on Monday. The stock has a market capitalization of $79.79 billion, a PE ratio of 13.95, a price-to-earnings-growth ratio of 1.16 and a beta of 0.66. The company has a current ratio of 0.87, a quick ratio of 0.58 and a debt-to-equity ratio of 1.15. GSK plc has a 12-month low of $33.67 and a 12-month high of $45.92. The stock’s fifty day simple moving average is $42.51 and its two-hundred day simple moving average is $41.23.

GSK (NYSE:GSKGet Free Report) last posted its earnings results on Wednesday, May 1st. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.94 by $0.15. The company had revenue of $9.34 billion for the quarter, compared to analyst estimates of $8.98 billion. GSK had a return on equity of 51.54% and a net margin of 14.62%. As a group, analysts expect that GSK plc will post 4.11 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, July 11th. Shareholders of record on Friday, May 17th will be paid a $0.3762 dividend. This represents a $1.50 annualized dividend and a yield of 3.91%. This is an increase from GSK’s previous quarterly dividend of $0.36. The ex-dividend date of this dividend is Thursday, May 16th. GSK’s dividend payout ratio (DPR) is 53.26%.

About GSK

(Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

Featured Articles

Institutional Ownership by Quarter for GSK (NYSE:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.